Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and
Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help prevent HIV infection, thanks to positive data from a phase 1/2a trial.
Leading UK politicians have called for an HIV prevention drug to be made available across the NHS, after a court ruling paved the way for cheap generic versions of Gilead’s Truvada.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
